Focus on Transcatheter Aortic Valve Implantation in Low-Risk Patients

In just more than a decade since the first patients were enrolled in the PARTNER I trial, transcatheter aortic valve implantation (TAVI) has become the treatment of choice for elderly high-risk patients with severe aortic stenosis. Robust randomized trial data from intermediate-risk patient cohorts also support the net superiority of TAVI when undertaken via femoral approach. As the focus now moves to evidence-based treatment of low-risk patients, ongoing trials must address a number of key differentiating features that uniquely define this group of often-younger patients with fewer comorbidities and longer life expectancy. This chapter focuses on the clinical and procedural challenges associated with the percutaneous treatment of the large low-risk cohort of patients with severe aortic stenosis.